This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Improving Antidepressant Adherence

Charles B. Nemeroff, MD, PhD

Published: December 1, 2003

Article Abstract

Frequently, patients suffering from depressive disorders discontinue antidepressant treatment dueto the unpleasant side effects of these medications, particularly in the first month of therapy. Goodtolerability (particularly in the early stages of treatment), patient education, and the quality of the relationshipbetween physicians and patients are all common determining factors of patient adherence.Controlled-release antidepressant agents have the potential to improve tolerability early in the courseof therapy, one of the most likely periods of dropout from treatment. Side effects for controlled-releaseformulations are often more favorable because controlled-release formulations exhibit lowerpeak plasma drug concentrations when compared with immediate-release formulations. Venlafaxineextended-release (XR), bupropion sustained-release (SR), and paroxetine controlled-release (CR) are3 commonly utilized controlled-release antidepressants that have demonstrated improvement overtheir immediate-release predecessors in reducing certain adverse effects.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 64

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...